Abnormalities in Glucose Blood Level during Antipsychotic Treatment in Schizophrenia Patients
DOI:
https://doi.org/10.3889/oamjms.2021.6294Keywords:
Antipsychotics, Hyperglycemia, Metabolic syndromeAbstract
Background: Schizophrenia is one of the mental disorder with many problematic issues, in both psychologically and socially. This disease requires provision of long-term antipsychotic therapy, hence could rise other potential health problems. Antipsychotic treatment can cause serious glucometabolic side-effects, including type 2 diabetes and hyperglycemic emergency. Recent attention has also been focused on antipsychotic-induced hyperglycemic emergencies experienced by new users of typical and atypical antipsychotic. Patients treated with atypical APDs have ~10 times higher risk in developing hyperglycaemic emergencies. In our pre-eliminary study, hyperglycemia condition in new patients occurs in four in seven patients who received typical and atypical antipsychotics. This condition is often overlooked and is not routinely evaluated. Moreover, it can develop into diabetes and increase the risk of morbidity and mortality in schizophrenia patients. In this study, we would like to determine the acute effects of metabolic (hyperglycemia) in patients treated with antipsychotic (Risperidone and Haloperidol) Measurement of blood sugar levels was performed in groups treated with haloperidol (N = 15) and treated with risperidone (N = 15). Plasma samples were taken at the beginning of treatment, in week IV, and in week VIII. The measurement of glucose levels was performed after meal and in early morning before breakfast (fasting blood glucose level 8 hours). Results: The blood sugar level after meals was significantly higher in the Risperidone group compared to the Haloperidol group (p <0.001) after IV and VIII weeks. Meanwhile, the fasting blood sugar level was significantly higher in the Risperidone group compared to the Haloperidol group after VIII weeks of treatment ( p <0.001). Conclusions: Both antipsychotics can cause an increase in blood sugar levels. Treatment with Risperidone significantly increased the blood sugar levels compared to treatment with haloperidol. Measurement of blood sugar level is needed to monitor the metabolic effect of antipsychotic, especially in patients treated with Risperidone. It is necessary to have dietary regulation and physical activities to prevent undesired metabolic side effects.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Mitchell AJ, Vancampfort D, Sweers K, Van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta analysis. Schizophr Bull. 2013;39(2):306-18. https://doi.org/10.1093/schbul/sbr148 Mid:22207632 DOI: https://doi.org/10.1093/schbul/sbr148
Best L, Yates AP, Reynolds GP. Actions of antipsychotic drugs on pancreatic β-cell function: Contrasting effects of clozapine and haloperidol. J Psychopharmacol 2005;19(6):597-60. https://doi.org/10.1177/0269881105056641 PMid:16272180 DOI: https://doi.org/10.1177/0269881105056641
Khalil RB. Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies. Clin Neuropharmacol. 2012;35(3):141-7. https://doi.org/10.1097/wnf.0b013e31824d5288 PMid:22592510 DOI: https://doi.org/10.1097/WNF.0b013e31824d5288
Boucher J, Kleinridders A, Kahn CR. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol. 2014;6(1):a009191. https://doi.org/10.1101/cshperspect.a009191 DOI: https://doi.org/10.1101/cshperspect.a009191
Boyda HN, Tse L, Procyshyn RM, Wong D, Wu TK, Pang CC, et al. A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in animal model. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(6):945-54. https://doi.org/10.1016/j.pnpbp.2010.04.024 PMid:20452386 DOI: https://doi.org/10.1016/j.pnpbp.2010.04.024
Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry. 1997;171:502-8. PMid:9519087 DOI: https://doi.org/10.1192/bjp.171.6.502
Deng C. Effects of antipsychotic medications on appetite, weight, and insulin resistance. Endocrinol Metab Clin North Am 2013;42(3):545-63. PMid:24011886 DOI: https://doi.org/10.1016/j.ecl.2013.05.006
Engl J, Laimer M, Niederwanger A, Kranebitter M, Starzinger M, Pedrini M, et al. Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Mol Psychiatry. 2005;10(12):1089-96. https://doi.org/10.1038/sj.mp.4001729 PMid:16130009 DOI: https://doi.org/10.1038/sj.mp.4001729
Han M, Deng C, Burne TH, Newell KA, Huang XF. Short-and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression. Psychoneuroendocrinology. 2008;33(5):569-80. https://doi.org/10.1016/j.psyneuen.2008.01.018 PMid:18358632 DOI: https://doi.org/10.1016/j.psyneuen.2008.01.018
Elizabeth AK. Risperidone-associated diabetes mellitus: A pharmacovigilance study. Pharmacotherapy. 2003;23(6):735-44. PMid:12820816 DOI: https://doi.org/10.1592/phco.23.6.735.32178
Longo DL, Fausi AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrison’s : Principles of Internal Medicine. 17th ed. New York: McGraw-Hill Medical; 2008. https://doi.org/10.1111/j.1445-5994.2008.01837.x DOI: https://doi.org/10.1111/j.1445-5994.2008.01837.x
Colton CW, Manderschied RW. Congruencies in increased mortality rates, years of potensial life lost, and causes of death among public mental health client in eight states. Prev Chronic Dis. 2006;2(2):A42. PMid:16539783
Manu P, Correl CU, van Winkel R, Wampers M, De Hert M. Prediabetes in patients treated with antipsychotic drugs. J Clin Psychiatry. 2012;73(4): 460-6. https://doi.org/10.4088/jcp.10m06822 PMid:22225552 DOI: https://doi.org/10.4088/JCP.10m06822
Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet. 2005;20(5):368-78. https://doi.org/10.2133/dmpk.20.368 PMid:16272755 DOI: https://doi.org/10.2133/dmpk.20.368
Ozasa R, Okada T, Nadanaka S, Nagamine T, Zyryanova A, Harding H, et al. The antipsychotic olanzapine induces apoptosis in insulin-secreting pancreatic β cells by blocking PERK-mediated translational attenuation. Cell Struct Funct. 2013;38(2):183-95. https://doi.org/10.1247/csf.13012 PMid:23812432 DOI: https://doi.org/10.1247/csf.13012
Wani RA, Dar MA, Margoob MA, Rather YH, Haq I, Shah MS. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia, before and after antipsychotic treatment. J Neurosci Rural Pract. 2015;6(1):17-22. https://doi.org/10.4103/0976-3147.143182 DOI: https://doi.org/10.4103/0976-3147.143182
Ferno J, Varela L, Skrede S, Vazquez MJ, Nogueiras R, Dieguez C, et al. Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation. PLoS One. 2011;6(6):e20571. https://doi.org/10.1371/journal.pone.0020571 PMid:21695181 DOI: https://doi.org/10.1371/journal.pone.0020571
Fleischhacker WW, Siu CO, Bodén R, Pappadopulos E, Karayal ON, Kahn RS. Metabolic risk factors in first-episode schizophrenia: Baseline prevalence and course analysed from the European first-episode schizophrenia trial. Int J Neuropsychopharmacol. 2013;16(5):987-95. https://doi.org/10.1017/s1461145712001241 PMid:23253821 DOI: https://doi.org/10.1017/S1461145712001241
Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry. 2011;68(6):609-16. https://doi.org/10.1001/ archgenpsychiatry.2011.2 PMid:21300937 DOI: https://doi.org/10.1001/archgenpsychiatry.2011.2
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Faisal Idrus, Theodorus Singara, Dwiwahyu Sunarto, Saidah Syamsuddin, Sonny T. Lisal (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
